日本癌症免疫療法市場報告（按療法類型、應用、最終用戶和地區分類，2026-2034年）

Japan Cancer Immunotherapy Market Report by Therapy Type, Application, End User, and Region 2026-2034

出版日期: 2026年01月01日 | 出版商:

IMARC | 英文 122 Pages | 商品交期: 5-7個工作天內

價格

簡介目錄

2025年，日本癌症免疫療法市場規模達80.842億美元。展望未來， IMARC Group預計到2034年，該市場規模將達到150.233億美元，2026年至2034年期間的複合年成長率（CAGR）為7.13%。推動市場成長的因素有很多，包括癌症發生率的上升、政府的支持性項目以及醫療保險的普及。

本報告解答的關鍵問題：

日本癌症免疫療法市場目前表現如何？未來幾年又將如何發展？
新冠疫情對日本癌症免疫療法市場產生了哪些影響？
日本癌症免疫療法市場按療法類型分類的組成是怎樣的？
日本癌症免疫療法市場按應用領域分類的組成是怎樣的？
日本癌症免疫療法市場以最終用戶分類的組成是怎樣的？
日本癌症免疫療法市場價值鏈的各個階段有哪些？
日本癌症免疫療法的關鍵促進因素和挑戰是什麼？
日本癌症免疫療法市場的結構是怎麼樣的？主要參與者有哪些？
日本癌症免疫療法市場的競爭程度如何？

Japan cancer immunotherapy market size reached USD 8,084.2 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 15,023.3 Million by 2034, exhibiting a growth rate (CAGR) of 7.13% during 2026-2034. The market is being propelled by several significant factors, including an increasing incidence of cancer cases, supportive government programs, and the widespread accessibility of medical insurance.

Cancer is a medical condition characterized by the uncontrolled growth and spread of certain cells in the body to various parts. Its development is often linked to factors such as alcohol or tobacco consumption, an unhealthy diet, exposure to air pollution, and a lack of physical activity. Individuals affected by cancer can experience significant health challenges, including feelings of anxiety, depression, fear of mortality, pain, stress, and even thoughts of suicide. Immunotherapy is an approach to cancer treatment involving the use of antibodies that bind to and inhibit the activity of proteins produced by cancer cells. This method helps strengthen the immune system's ability to identify and eliminate abnormal cancer cells within the body. Consequently, it finds widespread application in the treatment of various cancer types, including lung, breast, colorectal, melanoma, prostate, head and neck, thyroid, kidney, liver, cervical, bladder, ovarian, and skin cancers.

Japan Cancer Immunotherapy Market Trends:

In the context of the Japanese market, several significant factors are positively impacting the cancer immunotherapy sector. One of the primary drivers is the rising number of cancer cases, attributed to poor dietary habits and exposure to harmful substances among individuals worldwide. Additionally, there is a growing awareness regarding diverse cancer treatment options among the global population, contributing to market expansion. Furthermore, the increasing adoption of cancer immunotherapies is driven by their ability to offer prolonged progression-free survival (PFS) and overall survival (OS) compared to traditional anti-tumor therapies. The availability and accessibility of medical insurance, alongside rising healthcare expenditure, are presenting attractive growth prospects for industry investors. Moreover, there is a growing demand for treatment approaches with fewer adverse effects, which aligns with the increasing approval of novel immunotherapies and fuels market growth. Government agencies and non-profit organizations in various countries are actively promoting the adoption of cancer immunotherapy through widespread awareness campaigns focused on cancer prevention. Lastly, the market benefits from ongoing technological advancements in cancer treatment therapies, which are enhancing the efficiency of disease management strategies. These factors collectively contribute to the positive growth trajectory of the cancer immunotherapy market in Japan.

Japan Cancer Immunotherapy Market Segmentation:

Therapy Type Insights:

Monoclonal Antibodies
Cancer Vaccines
Checkpoint Inhibitors
Immunomodulators
Others

Application Insights:

Lung Cancer
Breast Cancer
Colorectal Cancer
Melanoma
Prostate Cancer
Head and Neck Cancer
Others

End User Insights:

Hospitals
Cancer Research Centers
Clinics
Others

Regional Insights:

Kanto Region
Kansai/Kinki Region
Central/ Chubu Region
Kyushu-Okinawa Region
Tohoku Region
Chugoku Region
Hokkaido Region
Shikoku Region
The report has also provided a comprehensive analysis of all the major regional markets, which include Kanto Region, Kansai/Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, and Shikoku Region.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

How has the Japan cancer immunotherapy market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the Japan cancer immunotherapy market?
What is the breakup of the Japan cancer immunotherapy market on the basis of therapy type?
What is the breakup of the Japan cancer immunotherapy market on the basis of application?
What is the breakup of the Japan cancer immunotherapy market on the basis of end user?
What are the various stages in the value chain of the Japan cancer immunotherapy market?
What are the key driving factors and challenges in the Japan cancer immunotherapy?
What is the structure of the Japan cancer immunotherapy market and who are the key players?
What is the degree of competition in the Japan cancer immunotherapy market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Cancer Immunotherapy Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Cancer Immunotherapy Market Landscape

5.1 Historical and Current Market Trends (2020-2025)
5.2 Market Forecast (2026-2034)

6 Japan Cancer Immunotherapy Market - Breakup by Therapy Type

6.1 Monoclonal Antibodies
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2020-2025)
- 6.1.3 Market Forecast (2026-2034)
6.2 Cancer Vaccines
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2020-2025)
- 6.2.3 Market Forecast (2026-2034)
6.3 Checkpoint Inhibitors
- 6.3.1 Overview
- 6.3.2 Historical and Current Market Trends (2020-2025)
- 6.3.3 Market Forecast (2026-2034)
6.4 Immunomodulators
- 6.4.1 Overview
- 6.4.2 Historical and Current Market Trends (2020-2025)
- 6.4.3 Market Forecast (2026-2034)
6.5 Others
- 6.5.1 Historical and Current Market Trends (2020-2025)
- 6.5.2 Market Forecast (2026-2034)

7 Japan Cancer Immunotherapy Market - Breakup by Application

7.1 Lung Cancer
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2020-2025)
- 7.1.3 Market Forecast (2026-2034)
7.2 Breast Cancer
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2020-2025)
- 7.2.3 Market Forecast (2026-2034)
7.3 Colorectal Cancer
- 7.3.1 Overview
- 7.3.2 Historical and Current Market Trends (2020-2025)
- 7.3.3 Market Forecast (2026-2034)
7.4 Melanoma
- 7.4.1 Overview
- 7.4.2 Historical and Current Market Trends (2020-2025)
- 7.4.3 Market Forecast (2026-2034)
7.5 Prostate Cancer
- 7.5.1 Overview
- 7.5.2 Historical and Current Market Trends (2020-2025)
- 7.5.3 Market Forecast (2026-2034)
7.6 Head and Neck Cancer
- 7.6.1 Overview
- 7.6.2 Historical and Current Market Trends (2020-2025)
- 7.6.3 Market Forecast (2026-2034)
7.7 Others
- 7.7.1 Historical and Current Market Trends (2020-2025)
- 7.7.2 Market Forecast (2026-2034)

8 Japan Cancer Immunotherapy Market - Breakup by End User

8.1 Hospitals
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2020-2025)
- 8.1.3 Market Forecast (2026-2034)
8.2 Cancer Research Centers
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2020-2025)
- 8.2.3 Market Forecast (2026-2034)
8.3 Clinics
- 8.3.1 Overview
- 8.3.2 Historical and Current Market Trends (2020-2025)
- 8.3.3 Market Forecast (2026-2034)
8.4 Others
- 8.4.1 Historical and Current Market Trends (2020-2025)
- 8.4.2 Market Forecast (2026-2034)

9 Japan Cancer Immunotherapy Market - Breakup by Region

9.1 Kanto Region
- 9.1.1 Overview
- 9.1.2 Historical and Current Market Trends (2020-2025)
- 9.1.3 Market Breakup by Therapy Type
- 9.1.4 Market Breakup by Application
- 9.1.5 Market Breakup by End User
- 9.1.6 Key Players
- 9.1.7 Market Forecast (2026-2034)
9.2 Kansai/Kinki Region
- 9.2.1 Overview
- 9.2.2 Historical and Current Market Trends (2020-2025)
- 9.2.3 Market Breakup by Therapy Type
- 9.2.4 Market Breakup by Application
- 9.2.5 Market Breakup by End User
- 9.2.6 Key Players
- 9.2.7 Market Forecast (2026-2034)
9.3 Central/ Chubu Region
- 9.3.1 Overview
- 9.3.2 Historical and Current Market Trends (2020-2025)
- 9.3.3 Market Breakup by Therapy Type
- 9.3.4 Market Breakup by Application
- 9.3.5 Market Breakup by End User
- 9.3.6 Key Players
- 9.3.7 Market Forecast (2026-2034)
9.4 Kyushu-Okinawa Region
- 9.4.1 Overview
- 9.4.2 Historical and Current Market Trends (2020-2025)
- 9.4.3 Market Breakup by Therapy Type
- 9.4.4 Market Breakup by Application
- 9.4.5 Market Breakup by End User
- 9.4.6 Key Players
- 9.4.7 Market Forecast (2026-2034)
9.5 Tohoku Region
- 9.5.1 Overview
- 9.5.2 Historical and Current Market Trends (2020-2025)
- 9.5.3 Market Breakup by Therapy Type
- 9.5.4 Market Breakup by Application
- 9.5.5 Market Breakup by End User
- 9.5.6 Key Players
- 9.5.7 Market Forecast (2026-2034)
9.6 Chugoku Region
- 9.6.1 Overview
- 9.6.2 Historical and Current Market Trends (2020-2025)
- 9.6.3 Market Breakup by Therapy Type
- 9.6.4 Market Breakup by Application
- 9.6.5 Market Breakup by End User
- 9.6.6 Key Players
- 9.6.7 Market Forecast (2026-2034)
9.7 Hokkaido Region
- 9.7.1 Overview
- 9.7.2 Historical and Current Market Trends (2020-2025)
- 9.7.3 Market Breakup by Therapy Type
- 9.7.4 Market Breakup by Application
- 9.7.5 Market Breakup by End User
- 9.7.6 Key Players
- 9.7.7 Market Forecast (2026-2034)
9.8 Shikoku Region
- 9.8.1 Overview
- 9.8.2 Historical and Current Market Trends (2020-2025)
- 9.8.3 Market Breakup by Therapy Type
- 9.8.4 Market Breakup by Application
- 9.8.5 Market Breakup by End User
- 9.8.6 Key Players
- 9.8.7 Market Forecast (2026-2034)

10 Japan Cancer Immunotherapy Market - Competitive Landscape

10.1 Overview
10.2 Market Structure
10.3 Market Player Positioning
10.4 Top Winning Strategies
10.5 Competitive Dashboard
10.6 Company Evaluation Quadrant

11 Profiles of Key Players

11.1 Company A
- 11.1.1 Business Overview
- 11.1.2 Services Offered
- 11.1.3 Business Strategies
- 11.1.4 SWOT Analysis
- 11.1.5 Major News and Events
11.2 Company B
- 11.2.1 Business Overview
- 11.2.2 Services Offered
- 11.2.3 Business Strategies
- 11.2.4 SWOT Analysis
- 11.2.5 Major News and Events
11.3 Company C
- 11.3.1 Business Overview
- 11.3.2 Services Offered
- 11.3.3 Business Strategies
- 11.3.4 SWOT Analysis
- 11.3.5 Major News and Events
11.4 Company D
- 11.4.1 Business Overview
- 11.4.2 Services Offered
- 11.4.3 Business Strategies
- 11.4.4 SWOT Analysis
- 11.4.5 Major News and Events
11.5 Company E
- 11.5.1 Business Overview
- 11.5.2 Services Offered
- 11.5.3 Business Strategies
- 11.5.4 SWOT Analysis
- 11.5.5 Major News and Events

12 Japan Cancer Immunotherapy Market - Industry Analysis

12.1 Drivers, Restraints, and Opportunities
- 12.1.1 Overview
- 12.1.2 Drivers
- 12.1.3 Restraints
- 12.1.4 Opportunities
12.2 Porters Five Forces Analysis
- 12.2.1 Overview
- 12.2.2 Bargaining Power of Buyers
- 12.2.3 Bargaining Power of Suppliers
- 12.2.4 Degree of Competition
- 12.2.5 Threat of New Entrants
- 12.2.6 Threat of Substitutes
12.3 Value Chain Analysis